These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 35008525)

  • 21. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
    Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
    Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
    Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
    Wang XF; Qian DZ; Ren M; Kato Y; Wei Y; Zhang L; Fansler Z; Clark D; Nakanishi O; Pili R
    Clin Cancer Res; 2005 May; 11(9):3535-42. PubMed ID: 15867257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
    Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
    Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetics Involvement in Oxaliplatin-Induced Potassium Channel Transcriptional Downregulation and Hypersensitivity.
    Pereira V; Lamoine S; Cuménal M; Lolignier S; Aissouni Y; Pizzoccaro A; Prival L; Balayssac D; Eschalier A; Bourinet E; Busserolles J
    Mol Neurobiol; 2021 Jul; 58(7):3575-3587. PubMed ID: 33772465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition.
    Shah RD; Jagtap JC; Mruthyunjaya S; Shelke GV; Pujari R; Das G; Shastry P
    J Cell Biochem; 2013 Apr; 114(4):854-63. PubMed ID: 23097134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
    Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
    PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Class I histone deacetylase inhibition modulates metalloproteinase expression and blocks cytokine-induced cartilage degradation.
    Culley KL; Hui W; Barter MJ; Davidson RK; Swingler TE; Destrument AP; Scott JL; Donell ST; Fenwick S; Rowan AD; Young DA; Clark IM
    Arthritis Rheum; 2013 Jul; 65(7):1822-30. PubMed ID: 23575963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
    Kakihana M; Ohira T; Chan D; Webster RB; Kato H; Drabkin HA; Gemmill RM
    J Thorac Oncol; 2009 Dec; 4(12):1455-65. PubMed ID: 20009910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
    Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
    Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventive action of benztropine on platinum-induced peripheral neuropathies and tumor growth.
    Cerles O; Gonçalves TC; Chouzenoux S; Benoit E; Schmitt A; Bennett Saidu NE; Kavian N; Chéreau C; Gobeaux C; Weill B; Coriat R; Nicco C; Batteux F
    Acta Neuropathol Commun; 2019 Jan; 7(1):9. PubMed ID: 30657060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.
    Minami T; Takeda M; Sata M; Kato H; Yano K; Sakai T; Tsujita R; Kawasaki K; Ito A
    Eur J Pharmacol; 2020 Aug; 880():173196. PubMed ID: 32416186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MS-275, a class I histone deacetylase inhibitor, protects the p53-deficient mouse against ischemic injury.
    Murphy SP; Lee RJ; McClean ME; Pemberton HE; Uo T; Morrison RS; Bastian C; Baltan S
    J Neurochem; 2014 May; 129(3):509-15. PubMed ID: 24147654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathological Mechanisms and Preventive Strategies of Oxaliplatin-Induced Peripheral Neuropathy.
    Egashira N
    Front Pain Res (Lausanne); 2021; 2():804260. PubMed ID: 35295491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
    Hui KF; Chiang AK
    Int J Cancer; 2014 Dec; 135(12):2950-61. PubMed ID: 24771510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
    Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
    Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel HDAC1/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell cycle regulation.
    Lee HY; Tang DW; Liu CY; Cho EC
    Chem Biol Interact; 2022 Jan; 352():109778. PubMed ID: 34929181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.